BioMark Diagnostics (BUX) Price & Analysis

Compare

3 Followers

BUX Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$0.18 - C$0.38

Previous CloseN/A

Volume0.00

Average Volume (3M)27.39K

Market Cap

C$35.73M

Enterprise ValueC$18.64M

Total Cash (Recent Filing)C$2.48M

Total Debt (Recent Filing)C$454.16K

Price to Earnings (P/E)―

Beta-0.40

Next Earnings

Nov 21, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding105,090,210

10 Day Avg. Volume9,965

30 Day Avg. Volume27,390

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$0.50

Price Target Upside38.89% Upside

Rating ConsensusHold

Number of Analyst Covering1

BioMark Diagnostics News

BioMark Diagnostics Expands into North Africa with Strategic Partnership

BioMark Diagnostics ( ($TSE:BUX) ) just unveiled an announcement. BioMark Diagnostics has announced a strategic partnership with SAMA...

30d ago

BioMark Diagnostics Expands Laboratory Services to Boost Lung Cancer Assay Commercialization

An update from BioMark Diagnostics ( ($TSE:BUX) ) is now available. BioMark Diagnostics Inc. has announced the expansion...

1M ago

BioMark Diagnostics Announces 2025 Achievements and Strategic Milestones for 2025-2026

BioMark Diagnostics ( ($TSE:BUX) ) has issued an announcement. BioMark Diagnostics Inc. announced its fiscal year 2025 achievements...

1M ago

BioMark Diagnostics Unveils AI Breakthrough in Early Lung Cancer Detection

An announcement from BioMark Diagnostics ( ($TSE:BUX) ) is now available. BioMark Diagnostics has announced a breakthrough in...

4M ago

BioMark Diagnostics Validates High Accuracy of Early-Stage Lung Cancer Test

BioMark Diagnostics ( ($TSE:BUX) ) has shared an announcement. BioMark Diagnostics has announced a significant publication in the...

4M ago

BioMark Diagnostics Uplists to OTCQB, Boosting U.S. Market Presence

BioMark Diagnostics ( ($TSE:BUX) ) has provided an announcement. BioMark Diagnostics Inc. has announced the uplisting of its...

4M ago

BioMark Diagnostics Closes Oversubscribed Private Placement to Boost Commercialization

BioMark Diagnostics ( ($TSE:BUX) ) has issued an announcement. BioMark Diagnostics Inc. announced the successful closing of its...

5M ago

BioMark Diagnostics Secures $2 Million Investment to Advance Cancer Detection Platform

BioMark Diagnostics ( ($TSE:BUX) ) just unveiled an update. BioMark Diagnostics Inc. has successfully secured a USD $2...

6M ago

BioMark Diagnostics Reaffirms Commitment to Rare Disease Research on Rare Disease Day 2025

BioMark Diagnostics ( ($TSE:BUX) ) has provided an announcement. BioMark Diagnostics Inc. has reaffirmed its commitment to rare...

6M ago

BioMark’s Breakthrough in Breast Cancer Diagnosis

BioMark Diagnostics (TSE:BUX) has released an update. BioMark Diagnostics has made a significant advancement in breast cancer diagnosis...

9M ago

BUX FAQ

What was BioMark Diagnostics’s price range in the past 12 months?

BioMark Diagnostics lowest stock price was C$0.18 and its highest was C$0.38 in the past 12 months.

What is BioMark Diagnostics’s market cap?

BioMark Diagnostics’s market cap is C$35.73M.

When is BioMark Diagnostics’s upcoming earnings report date?

BioMark Diagnostics’s upcoming earnings report date is Nov 21, 2025 which is in 71 days.

How were BioMark Diagnostics’s earnings last quarter?

Currently, no data Available

Is BioMark Diagnostics overvalued?

According to Wall Street analysts BioMark Diagnostics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does BioMark Diagnostics pay dividends?

BioMark Diagnostics does not currently pay dividends.

What is BioMark Diagnostics’s EPS estimate?

BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BioMark Diagnostics have?

BioMark Diagnostics has 105,090,210 shares outstanding.

What happened to BioMark Diagnostics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of BioMark Diagnostics?

Currently, no hedge funds are holding shares in TSE:BUX

Company Description

BioMark Diagnostics

BioMark Diagnostics (BUX) is a biotechnology company specializing in the development of innovative diagnostic tools and solutions for cancer detection and monitoring. The company focuses on the identification of biomarkers that enable early diagnosis and treatment options, primarily targeting sectors such as oncology and personalized medicine. BioMark's core products include non-invasive tests that utilize advanced molecular biology techniques to provide accurate and timely results for patients and healthcare providers.

BioMark Diagnostics (BUX) Earnings & Revenues

Historic Earnings Reports

BUX Stock 12 Month Forecast

Average Price Target

C$0.50

▲(38.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","1":"C$1","-1":"-C$1","-0.5":"-C$0.5","0.5":"C$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Feb<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.34,0.3523076923076923,0.3646153846153846,0.3769230769230769,0.38923076923076927,0.40153846153846157,0.41384615384615386,0.42615384615384616,0.43846153846153846,0.4507692307692308,0.46307692307692305,0.4753846153846154,0.4876923076923077,{"y":0.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.34,0.3523076923076923,0.3646153846153846,0.3769230769230769,0.38923076923076927,0.40153846153846157,0.41384615384615386,0.42615384615384616,0.43846153846153846,0.4507692307692308,0.46307692307692305,0.4753846153846154,0.4876923076923077,{"y":0.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.34,0.3523076923076923,0.3646153846153846,0.3769230769230769,0.38923076923076927,0.40153846153846157,0.41384615384615386,0.42615384615384616,0.43846153846153846,0.4507692307692308,0.46307692307692305,0.4753846153846154,0.4876923076923077,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.22,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.24,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.24,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.24,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.25,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.24,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.22,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.2,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.2,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.22,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.23,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.27,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >